

BIOINFORMANT

Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report



1ST AND ONLY MARKET RESEARCH FIRM TO
SPECIALIZE IN THE STEM CELL INDUSTRY

TABLE OF CONTENTS

1.	REPORT OVERVIEW	13	
1.1	Statement of the Report	13	
1.2	Executive Summary	15	
2.	INTRODUCTION	17	
2.1	Discovery of iPSCs	18	
2.2	Barriers in iPSC Application	19	
2.3	Timeline and Cost of iPSC Development	19	
2.4	Current Status of iPSCs Industry	20	
2.4.1	Share of iPSC-based Research within the Overall Stem Cell Industry	20	
2.4.2	Major Focuses of iPSC Companies	21	
2.4.3	Commercially Available iPSC-Derived Cell Types	21	
2.4.4	Relative Use of iPSC-Derived Cell Types in Toxicology Testing Assays	23	23
2.4.5	Toxicology/Safety Testing Assays using iPSC-Derived Cell Types	23	
2.5	Currently Available iPSC Technologies	25	
2.6	Advantages and Limitations of iPSCs Technology	27	
3.	INDUCED PLURIPOTENT STEM CELL (iPSC) TECHNOLOGY	28	
3.1	First iPSC generation from Mouse Fibroblasts, 2006	28	
3.2	First Human iPSC Generation, 2007	29	
3.3	Creation of CiRA, 2010	29	
3.4	First High-Throughput Screening Using iPSCs, 2012	30	
3.5	First iPSC Clinical Trial Approved in Japan, 2013	30	
3.6	The First iPSC-RPE Cell Sheet Transplantation for AMD, 2014	30	
3.7	EBiSC Founded, 2014	30	
3.8	First Clinical Trial using Allogeneic iPSCs for AMD, 2017	31	
3.9	Clinical Trials for Parkinson's disease using Allogeneic iPSCs, 2018	31	31
3.10	Commercial iPSC Plant SMaRT Established, 2018	31	
3.11	First iPSC Therapy Center in Japan, 2019	31	
3.12	The First U.S.-based NIH Sponsored Clinical Trial using iPSCs, 2019	32	32
3.13	Cynata Therapeutics' Worlds Largest Phase III Clinical Trial, 2020	32	32
4.	RESEARCH PUBLICATIONS ON iPSCs	33	
4.1	Categories of Research Publications	34	
4.2	Percent Share of Published Articles by Disease Type	35	
4.3	Number of Articles by Country	36	
5.	iPSCs: PATENT LANDSCAPE	38	
5.1	Timeline and Status of Patents	38	
5.2	Patent Filing Destinations	39	
5.2.1	Patent Applicant's Origin	40	
5.2.2	Top Ten Global Patent Applicants	41	
5.2.3	Collaborating Applicants of Patents	42	
5.3	Patent Application Trends iPSC Preparation Technologies	43	
5.4	Patent Application Trends in iPSC Differentiation Technologies	46	
5.5	Patent Application Trends in Disease-Specific Cell Technologies	47	47
6.	CLINICAL TRIALS INVOLVING iPSCs	50	
6.1	Current Clinical Trials Landscape	51	
6.1.1	Clinical Trials Involving iPSCs by Major Diseases	58	

6.1.2	Clinical Trials Involving iPSCs by Country	58
7.	FUNDING FOR iPSCs	60
7.1	Value of NIH Funding for iPSCs	61
7.1.1	NIH's Intended Funding Through its Component Organizations in 2020	64
7.1.2	NIH Funding for Select Universities for iPSC Studies	65
7.2	CIRM Funding for iPSCs	67
8.	GENERATION OF INDUCED PLURIPOTENT STEM CELLS: AN OVERVIEW	69
8.1	Reprogramming Factors	71
8.1.1	Pluripotency-Associated Transcription Factors	71
8.1.2	Different Cell Sources and Different Combinations of Factors	73
8.1.3	Delivery of Reprogramming Factors	73
8.1.4	Integrative Delivery Systems	74
8.1.4.1	Integrative Viral Vectors	74
8.1.4.2	Integrative Non-Viral Vectors	75
8.1.5	Non-Integrative Delivery Systems	75
8.1.5.1	Non-Integrative Viral Vectors	75
8.1.5.2	Non-Integrative Non-Viral Delivery	75
8.2	Overview of Four Key Methods of Gene Delivery	75
8.3	Comparative Effectiveness of Different Vector Types	76
8.4	Genome Editing Technologies in iPSCs Generation	77
9.	HUMAN iPSC BANKING	80
9.1	Cell Sources for iPSCs Banking	81
9.2	Reprogramming methods used in iPSC Banking	81
9.2.1	Factors used in reprogramming by Different Banks	81
9.3	Workflow in iPSC Banks	82
9.4	Existing iPSC Banks	83
9.4.1	California Institute for Regenerative Medicine (CIRM)	83
9.4.1.1	CIRM iPSC Repository	84
9.4.1.2	Key Partnerships Supporting CIRM's iPSC Repository	85
9.4.2	Regenerative Medicine Program (RMP)	85
9.4.2.1	Research Grade iPSC Lines for Orphan and Rare Diseases from RMP	86
9.4.2.2	RMP's Stem Cell Translation Laboratory (SCTL)	88
9.4.3	Center for iPS Cell Research and Application (CiRA)	88
9.4.3.1	FiT: Facility for iPS Cell Therapy	88
9.4.4	European Bank for Induced Pluripotent Stem Cells (EBiPC)	89
9.4.5	Korean Society for Cell Biology (KSCB)	90
9.4.6	Human Induced Pluripotent Stem Cell Initiative (HipSci)	90
9.4.7	RIKEN – BioResource Research Center (BRC)	90
9.4.8	Taiwan Human Disease iPSC Consortium	92
9.4.9	WiCell	93
10.	BIOMEDICAL APPLICATIONS OF iPSCs	94
10.1	iPSCs in Basic Research	95
10.1.1	Understanding Cell Fate Control	95
10.1.2	Cell Rejuvenation	95
10.1.3	Studying Pluripotency	95
10.1.4	Tissue and Organ Development and Physiology	96
10.1.5	Generation of Human Gametes from iPSCs	96
10.1.6	Providers of iPSC-Related Services for Researchers	96
10.2	iPSCs in Drug Discovery	98

10.2.1	Drug Discovery for Cardiovascular Disease using iPSCs	99
10.2.2	Drug Discovery for Neurological and Neuropsychiatric Diseases	100
10.2.3	Drug Discovery for Rare Diseases using iPSCs	102
10.3	iPSCs in Toxicology Studies	104
10.3.1	Relative Use of iPSC-Derived Cell Types within Toxicity Testing	106
10.4	iPSCs in Disease Modeling	107
10.4.1	Cardiovascular Diseases Modeled with iPSCs	112
10.4.2	Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling	113
10.4.3	Proportion of iPSC Sources in Cardiac Studies	114
10.4.4	Proportion of Vector Types used in Reprogramming	115
10.4.5	Proportion of Differentiated Cardiomyocytes used in Disease Modeling	116
10.4.6	iPSC-Derived Organoids for Modeling Development and Disease	117
10.4.7	Modeling Liver Diseases using iPSC-derived Hepatocytes	118
10.4.8	iPSCs in Neurodegenerative Disease Modeling	120
10.4.9	Cancer-Derived iPSCs	125
10.5	iPSCs within Cell-Based Therapies	126
10.5.1	iPSC-Derived Therapeutics under Development Worldwide	127
10.5.1.1	Clinical Trials for AMD	129
10.5.1.2	Autologous iPSC-RPE for AMD	130
10.5.1.3	Allogeneic iPSC-RPE for AMD	130
10.5.1.4	iPSC-Derived Dopaminergic Neurons for Parkinson's disease	130
10.5.1.5	iPSC-Derived NK Cells for Solid Cancers	131
10.5.1.6	iPSC-derived Cells for GvHD	131
10.5.1.7	iPSC-derived Cells for Spinal Cord Injury	131
10.5.1.8	iPSC-derived Cardiomyocytes for Ischemic Cardiomyopathy	131
10.5.1.9	Cynata's CYP-001 for Acute Respiratory Distress Syndrome (ARDS)	132
10.5.1.10	Cynata's CYP-004 for Osteoarthritis	132
10.5.1.11	Cynata's CYP-002 for Critical Limb Ischemia (CLI)	132
10.5.1.12	iPSC-Derived RPE Cells for Age-Related Macular Degeneration	132
10.5.1.13	Stem Cell Treatment for Aplastic Anemia	133
10.5.1	All Known Companies Developing iPSC-Derived Cell Therapeutics Worldwide	133
10.5.2	U.S. Clinical Trials Involving iPSCs	135
11.	OTHER NOVEL APPLICATIONS OF iPSCs	137
11.1	iPSCs in Tissue Engineering	137
11.1.1	3D Bioprinting Techniques	137
11.1.2	Biomaterials	138
11.1.3	3D Bioprinting Strategies	138
11.1.4	Bioprinting Undifferentiated iPSCs	138
11.1.5	Bioprinting iPSC-Differentiated Cells	139
11.2	iPSCs in Animal Conservation	142
11.2.1	iPSC Lines for the Preservation of Endangered Species of Animals	142
11.2.2	iPSCs in Wildlife Conservation	143
11.3	iPSCs and Cultured Meat	145
11.3.1	Funding Raised by Cultured Meat Companies	146
11.3.4	Global Market for Cultured Meat	147
12.	DEAL-MAKING WITHIN THE iPSC SECTOR	149
12.1	Novo Nordisk's Deal with Heartseed	149
12.2	Partnership between Neuropath Biotechnology Ltd. and Hopstem Biotechnology	149
12.3	License Agreement between FUJIFILM Cellular Dynamics and Sana Biotechnology	150
12.4	Century Therapeutics Closes \$160 Million Series C Financing	150
12.5	Bluerock Gains Access to Ncardia's iPSCs-derived Cardiomyocytes	150

12.6	Fate Therapeutics' deal with Janssen Biotech	151
12.7	Century Therapeutics Acquires Empirica Therapeutics	151
12.8	\$250 million Raised by Century Therapeutics	151
12.9	BlueRock Therapeutics Launched with \$225 Million	151
12.10	Collaboration between Allogene Therapeutics and Notch Therapeutics	152
12.11	Acquisition of Semma Therapeutics by Vertex Therapeutics	152
12.12	Evotec's Extended Collaboration with BMS	152
12.13	Licensing Agreement between Allele Biotechnology and Astellas Pharma	153
12.14	Codevelopment Agreement between Allele & SCM Lifesciences	153
12.15	Fate Therapeutics Signs \$100 Million Deal with Janssen	153
12.16	Allele's Deal with Alpine Biotherapeutics	153
12.17	Editas and BlueRock's Development Agreement	154
12.18	Avery Therapeutics and I Peace, Inc. Sign Service Agreement	154
12.19	Evotec SE Signed a Licensing and Investment Agreement with panCELLa, Inc.	154
13.	MARKET OVERVIEW	155
13.1	Global Market for iPSCs by Geography	157
13.2	Global Market for iPSCs by Technology	158
13.3	Global Market for iPSCs by Biomedical Application	160
13.4	Global Market for iPSCs by Cell Types	162
3.5	Market Drivers	164
13.6	Market Restraints	164
13.6.1	Economic Issues	164
13.6.2	Genomic Instability	165
13.6.3	Immunogenicity	165
13.6.4	Biobanking of iPSCs	165
14.	iPSC COMPANY PROFILES	166
14.1	Addgene, Inc.	166
14.1.1	Viral Plasmids	166
14.2	Aleph Farms	167
14.3	Allele Biotechnology and Pharmaceuticals, Inc.	168
14.3.1	iPSC Reprogramming and Differentiation	168
14.4	AMS Biotechnology Europe, Ltd. (AMSBIO)	169
14.4.1	Services	169
14.4.2	Products	169
14.4.3	Corneal Epithelial Cells Cultured in StemFit in Clinical Trials	171
14.5	ALSTEM, INC.	172
14.5.1	Products	172
14.5.2	Services	172
14.6	Applied Biological Materials, Inc. (ABM)	173
14.6.1	Gene Expression Vectors and Viruses	173
14.7	Applied StemCell, Inc.	174
14.7.1	Services & Products	174
14.8	American Type Culture Collection (ATCC)	175
14.8.1	Product	175
14.9	Applied StemCell (ASC), Inc.	176
14.9.1	Products	176
14.10	Aruna Bio, Inc.	177
14.10.1	Program in Stroke	177
14.10.2	Exosomes as Therapeutics	177
14.11	Aspen Neuroscience, Inc.	178
14.11.1	Technology	178

14.12	Avery Therapeutics	179	
14.12.1	MyCardia	179	
14.13	Axol Bioscience, Ltd.	180	
14.13.1	iPSC-derived Cells	180	
14.13.2	Disease Models	180	
14.13.3	Primary Cells	181	
14.13.4	Media & Reagents	181	
14.13.5	Services	181	
14.14	Beckman Coulter Life Sciences	182	
14.14.1	Cell Counters, Sizers and Media Analyzers	182	
14.15	BD Biosciences	183	
14.15.1	Products	183	
14.16	BioCat GmbH	184	
14.16.1	Products & Services	184	
14.17	BlueRock Therapeutics	185	
14.17.1	CELL + GENE Platform	185	
14.18	BrainXell	186	
14.18.1	Products	186	
14.19	Cellaria	187	
14.19.1	Product	187	
14.20	Cell Biolabs, Inc.	188	
14.20.1	Products	188	
14.21	CellGenix GmbH	189	
14.21.1	Products	189	
14.22	Cell Signaling Technology	190	
14.22.1	Products	190	
14.23	Cellular Engineering Technologies (CET)	191	
14.23.1	iPS Cell Lines	191	
14.24	Cellular Dynamics International, Inc.	192	
14.24.1	Products	192	
14.25	Censo Biotechnologies, Ltd.	194	
14.25.1	Human iPSC Reprogramming Services	194	
14.25.2	iPSC Gene Editing Services	194	
14.25.3	iPSC Target Validation and Assay Services	194	
14.26	Century Therapeutics, LLC	195	
14.26.1	Allogeneic Immune Cell Therapy	195	
14.27	CiRA	196	
14.27.1	Collaborations	196	
14.28	Corning, Inc.	197	
14.28.1	Products	197	
14.29	Creative Bioarray	199	
14.29.1	Products	199	
14.30	Cynata Therapeutics Ltd.	201	
14.30.1	Cymerus MSCs	201	
14.30.2	Cynata's Lead in iPSC-based Clinical Trials	201	
14.30.2.1	CYP-001	202	
14.30.2.2	CYP-002	202	
14.30.2.3	CYP-004	203	
14.30.2.4	MEND Clinical Trial	203	
14.31	Cytovia Therapeutics	204	
14.31.1	iPSC CAR NK Cells	204	
14.32	DefiniGEN	205	
14.32.1	OptiDIFF iPSC Platform	205	

14.32.2	Service	205	
14.32.3	Patient-Derived Custom Cell Lines	205	
14.32.4	Hepatocytes WT	206	
14.32.5	Hepatocyte A1ATD	206	
14.32.6	Hepatocyte GSD1a	206	
14.32.7	Hepatocyte NAFLD	206	
14.32.8	Hepatocyte FH207		
14.32.9	Pancreatic WT	207	
14.32.10	Pancreatic MODY3	207	
14.33	Evotec A.G.	208	
14.33.1	iPSC-Based Drug Discovery Platform	208	
14.34	Fate Therapeutics, Inc.	209	
14.34.1	iPSC Platform	209	
14.34.2	Collaboration with ONO Pharmaceutical Co., Ltd.	209	
14.34.3	Collaboration with Memorial Sloan-Kettering Cancer Center	210	
14.34.4	Collaboration with University of California, San Diego	210	
14.34.5	Collaboration with Oslo University Hospital	210	
14.35	FUJIFILM Cellular Dynamics, Inc.	211	
14.35.1	iCell Products	211	
14.35.2	MyCell Products	211	
14.35.3	FCDI's Partners & Providers	211	
14.35.4	Groundbreaking Cellular Therapy Applications	213	
14.35.5	New Paradigm for Drug Discovery	213	
14.35.6	FCDI & Stem Cell Banking	214	
14.36	GeneCopoeia, Inc.	215	
14.36.1	Products & Services	215	
14.37	GenTarget, Inc.	217	
14.37.1	Products	217	
14.37.2	Services	217	
14.38	Healios KK	218	
14.38.1	Healios' iPSCs for Regenerative Medicine	218	
14.39	Heartseed, Inc.	219	
14.39.1	Technology	219	
14.40	Hopstem Biotechnology LLC	220	
14.40.1	Products & Services	220	
14.41	InvivoGen	221	
14.41.1	Products	221	
14.42	iPS Portal, Inc.	222	
14.42.1	Services	222	
14.43	I Peace, Inc.	223	
14.43.1	Mass Production of iPSCs	223	
14.44	iXCells Biotechnologies	224	
14.44.1	Products	224	
14.45	Lonza Group, Ltd.	225	
14.45.1	Nucleofector Technology	225	
14.46	Merck/Sigma Aldrich	226	
14.46.1	Products	226	
14.47	Megakaryon Corporation	227	
14.47.1	Technology	227	
14.48	Metrion Biosciences, Ltd.	228	
14.48.1	Cardiac Translational Assays	228	
14.49	Miltenyi Biotec B.V. & Co. KG	229	
14.49.1	Cell Manufacturing Platform	229	

14.50	Rue Adrienne Bolland	230
14.50.1	iPSC Solutions for Cell Therapy	230
14.50.2	Drug Safety and Toxicity Services	230
14.51	NeuCyte	231
14.51.1	Technology	231
14.52	Newcells Biotech	232
14.52.1	Expertise	232
14.52.2	iPSC Reprogramming Services	232
14.52.3	Assay Products and Services	232
14.52.4	Assay Development	233
14.53	Novo Nordisk A/S	233
14.53.1	Partnership with HeartSeed	233
14.54	PeproTech	234
14.54.1	Products	234
14.55	Phenocell SAS	235
14.55.1	Human iPSCs	235
14.56	Platelet BioGenesis	236
14.56.1	Technology	236
14.57	Pluricell Biotech	237
14.57.1	Pluricell's Projects	237
14.58	PromoCell GmbH	238
14.58.1	Products	238
14.59	Qiagen	239
14.59.1	Single Cell Analysis	239
14.60	R&D Systems, Inc.	240
14.60.1	Products	240
14.61	ReproCELL	241
14.61.1	Services	241
14.61.2	Products	241
14.62	RHEINCELL Therapeutics GmbH	242
14.62.1	GMP-Grade iPSC Products	242
14.62.2	Services	242
14.63	Stemson Therapeutics	243
14.63.1	Hair Follicle Biology	243
14.64	TEMCELL Technologies	244
14.64.1	Products	244
14.65	Stemina Biomarker Discovery	245
14.65.1	Cardio quickPredict	245
14.65.2	devTOX quickPredict	245
14.66	Synthego Corp.	246
14.66.1	CRISPR-Edited iPSCs	246
14.67	System Biosciences (SBI)	247
14.67.1	Products	247
14.68	Takara Bio	248
14.68.1	Stem Cell Research Products	248
14.69	Takeda Pharmaceutical Co., Ltd.	249
14.69.1	Collaboration between CiRA and Takeda	249
14.69.2	FUJIFILM's Collaboration with Takeda	249
14.70	Tempo Bioscience	250
14.70.1	Human Cell Models	250
□	Tempo-iSenso: Human iPSC-derived Sensory Neurons	250
14.71	Thermo Fisher Scientific, Inc.	251
14.71.1	Products for Stem Cell Culture	251

14.71.2	Products for Stem Cell Characterization	251
14.71.3	Products for Stem Cell Engineering	251
14.72	TreeFrog Therapeutics	252
14.72.1	C-Stem Technology	252
14.73	VistaGen Therapeutics, Inc.	253
14.73.1	CardioSafe 3D	253
14.74	Waisman Biomanufacturing	254
14.74.1	GMP iPSCs	254
14.75	xCell Science, Inc.	255
14.75.1	Control Lines	255
14.75.2	Products	255
14.75.3	Services	255
14.76	Yashraj Biotechnology, Ltd.	256
14.76.1	Products and Services for Drug Discovery	256

INDEX OF FIGURES

FIGURE 2.1:	The Share of iPSC-related Research Compared with other Stem Cell Types	20
FIGURE 2.2:	Major Focuses of iPSC Companies	21
FIGURE 2.3:	Commercially Available iPSC-Derived Cell Types	22
FIGURE 2.4:	Relative Use of iPSC-Derived Cell Types in Toxicology/Safety Testing Assays	23
FIGURE 2.5:	Toxicology/Safety Testing Assays using iPSC-Derived Cell Types	24
FIGURE 3.1:	CiRA's Budget of ¥6.37 Billion	29
FIGURE 4.1:	Number of Research Publications on iPSCs in PubMed.gov, 2006-2020	34
FIGURE 4.2:	Percent Share of Published Articles by Research Themes	35
FIGURE 4.3:	Percent Share of Published Articles by Disease Type	36
FIGURE 4.4:	Percent Share of iPSC Research Publications by Country	37
FIGURE 5.1:	Number of Patents Granted, Being Sought, and "Dead"	38
FIGURE 5.2:	Patent Families by Filing Jurisdiction	40
FIGURE 5.3:	Patent Families by Applicant Origin	41
FIGURE 5.4:	Top Ten Global Applicants	42
FIGURE 5.5:	Top Ten Global Collaborators on PSC/iPSC Patents	43
FIGURE 5.6:	Share of Patents on iPSC Preparation Technologies by Geography	44
FIGURE 5.7:	Percent Share of iPSC Preparation Methods in the U.S., Japan and Europe	45
FIGURE 5.8:	Percent Share of Patents Related to Cell Types Differentiated from iPSCs	46
FIGURE 5.9:	Percent Share of Patent Applications for Disease-Specific Cell Technologies	48
FIGURE 5.10:	Percent Share of Patents Representing Different Disorders	49
FIGURE 6.1:	Number of Clinical Trials Involving iPSCs by Year, 2006-2020	50
FIGURE 6.2:	Clinical Trials Involving iPSCs by Major Diseases	58
FIGURE 6.3:	Clinical Trials Involving iPSCs by Country	59
FIGURE 7.1:	Number of NIH Funding for iPSC Projects, 2010-2020	60
FIGURE 7.2:	Value of NIH Funding for iPSCs by Year, 2010-2020	61
FIGURE 8.1:	Overview of iPSC Technology	69
FIGURE 8.2:	Generation of iPSCs from MEF Cultures through 24 Factors by Yamanaka	70
FIGURE 8.3:	The Roles of OSKM Factors in the Induction of iPSCs	71
FIGURE 8.4:	Schematic Representation of Delivery Methods for iPSCs Induction	74
FIGURE 8.5:	Overview of Four Key Methods of Gene Delivery	76
FIGURE 9.1:	Workflow in iPSC Banks	83
FIGURE 10.1:	Biomedical Applications of iPSCs	94
FIGURE 10.2:	Relative Use of iPSC-Derived Cell Types in Toxicity Testing	106
FIGURE 10.3:	A Schematic for iPSC-Based Disease Modeling	107
FIGURE 10.4:	Proportion of iPS Cell Lines Generated by Disease Type	114

FIGURE 10.5: Proportion of iPSC Sources in Cardiac Studies	115
FIGURE 10.6: Proportion of Vector Types used in Reprogramming	116
FIGURE 10.7: The Proportion of Differentiated Cardiomyocyte Types	117
FIGURE 10.8: Schematic for iPSC-Based Cell Therapy	126
FIGURE 11.1: Schematic Representation of Printing Techniques used for iPSC Bioprinting	139
FIGURE 11.2: Schematic Showing the use of iPSCs in Protecting Endangered Species	144
FIGURE 11.3: Funding raised by Cultured Meat Companies, 2016-2019	146
FIGURE 11.4: Estimated Global Market for Cultured Meat, 2023-2030	148
FIGURE 13.1: Estimated Global Market for iPSCs by Geography through 2026	157
FIGURE 13.2: Estimated Global Market for iPSCs by Technology through 2026	159
FIGURE 13.3: Estimated Global Market for iPSCs by Biomedical Application through 2026	162
FIGURE 13.4: Estimated Global Market Share for Differentiated Cell Types, 2020	163
FIGURE 14.1: Comparison of Conventional Meat Production and Cultured Meat Production	167

INDEX OF TABLES

TABLE 2.1: Companies Offering Commercially Available iPSC Technologies	26
TABLE 2.2: Advantages and Limitations of iPSC Technology	27
TABLE 3.1: Timeline of the Most Important Milestones in iPSC Research, 2006-2019	28
TABLE 4.1: Number of Research Publications on iPSCs in PubMed.gov, 2006-2021	33
TABLE 5.1: Patent Families by Filing Jurisdiction	39
TABLE 5.2: Patents Granted and Patents Pending in the Global Patent Landscape	49
TABLE 6.1: Select Clinical Trials involving iPSCs as of May 2021	51
TABLE 7.1: NIH Funding for iPSC Projects in 2020	62
TABLE 7.1: NIH's Intended Funding Through its Component Organizations in 2020	65
TABLE 7.2: NIH Funding for Select Universities/Organizations for iPSC Studies	65
TABLE 7.3: CIRM Funding for Clinical Trials Involving iPSCs	67
TABLE 8.1: Characterization of iPSCs	70
TABLE 8.2: Reprogramming Factors used in the Generation of iPSCs	72
TABLE 8.3: Different Cell Sources and Different Combinations of Reprogramming Factors	73
TABLE 8.1: Comparative Effectiveness of Different Vector Types	77
TABLE 8.2: iPSC Disease Models using Isogenic Control Lines Generated by CRISPR/Cas9	78
TABLE 9.1: Cell Sources and Reprogramming Agents used in iPSCs Banks	82
TABLE 9.2: Diseased iPSC Lines Available in CIRM Repository	84
TABLE 9.3: CIRMS' iPSC Initiative Awards	85
TABLE 9.4: Research Grade iPSCs Available with RMP	86
TABLE 9.5: Research Grade iPSC Lines for Orphan and Rare Diseases Available with RMP	87
TABLE 9.6: SCTL's Collaborations	88
TABLE 9.7: A Partial List of iPSC Lines Available with EBiPC	89
TABLE 9.8: List of Disease-Specific iPSCs Available with RIKEN	90
TABLE 9.9: An Overview of iPSC Banks Worldwide	93
TABLE 10.1: Providers of iPS Cell Lines and Parts Thereof for Research	97
TABLE 10.2: Comparison of hiPSC-Based & Animal-Based Drug Discovery	98
TABLE 10.3: Drug Discovery for Cardiovascular Diseases using iPSCs	99
TABLE 10.4: Drug Discovery for Neurological and Neuropsychiatric Diseases using iPSCs	101
TABLE 10.5: Drug Discovery for Rare Diseases using iPSCs	102
TABLE 10.6: Examples of Drug Testing in iPSC-Derived Disease Models	104
TABLE 10.7: Published Human iPSC Disease Models	108
TABLE 10.8: Partial List of Cardiovascular and Related Diseases Modeled with iPSCs	113
TABLE 10.9: iPSC-Derived Organoids for Modeling Development and Disease	118
TABLE 10.10: Liver Diseases and Therapeutic Interventions Modeled using iPSCs	119
TABLE 10.11: Examples of iPSC-Based Neurodegenerative Disease Modeling	121

TABLE 10.12: Cancer-Derived iPSCs	125
TABLE 10.13: iPSC-Derived Cell Therapeutics Being Tested within Clinical Trials Worldwide	127
TABLE 10.14: U.S. Clinical Trials Involving iPSCs	135
TABLE 11.1: Features of Different Bioprinting Techniques	140
TABLE 11.2: Bioprinting of iPSC-Derived Tissues	141
TABLE 11.3: Timeline of Achievements Made using iPSCs for Conservation of Animals	143
TABLE 11.4: Companies Working on Meat Production based on Cellular Agriculture	145
TABLE 13.1: Estimated Global Market for iPSCs by Geography through 2027	157
TABLE 13.2: Estimated Global Market for iPSCs by Technology through 2027	159
TABLE 13.3: Estimated Global Market for iPSCs by Biomedical Application through 2027	161
TABLE 13.4: Estimated Global Market for iPSCs by Differentiated Cell Types, through 2027	163



About BioInformant

BioInformant is the first and only market research firm to specialize in the stem cell industry.

BioInformant research has been cited by prominent news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine.

Serving Fortune 500 companies that include Pfizer, Goldman Sachs, and GE Healthcare, BioInformant is your global leader in stem cell industry data.

